Last updated: April 25, 2026
What does PT2361090 cover, and where does it sit in the Portugal drug patent landscape?
PT2361090 is a Portugal (PT) patent application/publication and is treated as a drug-technology asset within the Portuguese national patent stack, with scope best understood through: (1) the independent claims (subject-matter boundaries), (2) the claim dependencies (added technical limitations), (3) the specification’s defined terms (what “the invention” means in the Portuguese examination record), and (4) family-level counterparts (what was already disclosed in priority filings and how later claim sets evolved).
Scope and claims analysis cannot be completed from the information provided in this request. A PT publication number alone is not sufficient to extract the claim text, claim numbering, applicant/assignee, filing and priority dates, IPC/CPC tags, or linked family documents needed to produce a complete, accurate claim-by-claim scope map and landscape comparison.
No patent landscape conclusions can be stated without the actual PT2361090 claim set and bibliographic record (or the corresponding full text/patent family documents that contain the claim language).
What is PT2361090’s claim scope (independent claims and dependent limits)?
Cannot be determined with the required precision without the full claim text for PT2361090 (independent claims, dependent claim chain, key definitions, and claim construction markers such as “comprising,” “consisting of,” product-by-process language, and dose/regimen limitations).
What subject-matter does PT2361090 protect (formulation, method, use, or device)?
Cannot be determined without the claim categories in PT2361090 (e.g., pharmaceutical composition claims vs. therapeutic method claims vs. second medical use claims).
How broad is the protection in practice (breadth vs. enforceability factors)?
Cannot be determined without the claim wording, including:
- whether the claims are Markush-style or open-ended (“comprising”)
- whether they require specific excipients/active forms
- whether they specify molecular identity or functional recitations
- whether dosage/regimen endpoints are claimed
- whether the claims require clinical parameters (Cmax, AUC, half-life, stability) or process conditions
What is the family structure and how does it affect the Portugal scope?
Cannot be determined without bibliographic data for PT2361090:
- priority applications and dates
- continuation/divisional paths
- claim amendments across family members
- whether Portugal claims mirror EP/WO claims or diverge
Where does PT2361090 sit in Portugal’s patent landscape (related filings, likely collisions, and regulatory interaction)?
Cannot be determined without:
- CPC/IPC classification for PT2361090
- assignee/applicant identity
- active ingredient(s) or therapeutic area
- linkage to any marketing authorization and any SPCs (if present)
- identification of “near” patents in Portugal by class and assignee (or by same priority)
Key Takeaways
- PT2361090’s scope and claims cannot be analyzed to the level required for a business-grade patent landscape without the actual PT publication claim text and bibliographic record.
- No reliable conclusions can be made about claim breadth, likely enforceability, family dependency, or Portugal landscape collisions without document-specific data.
FAQs
-
Is PT2361090 an SPC or a standard patent application?
Cannot be determined without the PT bibliographic record and legal status data.
-
Does PT2361090 likely claim a formulation, a method of treatment, or a use?
Cannot be determined without the claim categories and claim language.
-
How do PT national claims typically interact with EU/WO families for the same invention?
Interaction depends on whether Portugal claims mirror or diverge from priority/EP/WO claim sets, which cannot be assessed without the family documents.
-
Can PT2361090 be used to block generic entry in Portugal?
Whether it is enforceable against generics depends on the exact claim scope (active ingredient vs. formulation vs. method/use) and enforceability status, which cannot be assessed without the claim text and status.
-
What is the fastest way to build a Portugal landscape around PT2361090?
It starts with mapping its CPC/IPC tags, assignee, therapeutic target, and claim elements, which requires the publication’s full record.
References
[1] PT2361090 (Portugal patent publication)
